This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CDK9 / Cyclin-dependent kinase 9 · IHC design guide
Design Immunohistochemistry for CDK9
Plan CDK9 IHC in paraffin sections around widespread nuclear staining (HPA tissue IHC). This guide covers fixation, detection and scoring by cell population, with cytoplasmic redistribution as a possible source of variation (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CDK9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Ubiquitous nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | Nuclear staining across diverse cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M00794) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Cytoplasmic translocation may alter nuclear signal (UniProt) | |
| Regulation | Replication stress recruits CDK9 to chromatin (UniProt) | |
| Isoform / epitope | 2 isoforms; check epitope coverage for each (UniProt) |
Section 1
Recommended CDK9 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 heat retrieval (datasheet M00794). The four published IHC protocols below report CDK9 staining in colorectal, ovarian, and endometrial tissues (PMC10045754; PMC8136118; PMC7551504; PMC6865572).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M00794) |
| Fixation | Image fixative and duration unreported (datasheet M00794); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M00794); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M00794) |
| Primary antibody | Rabbit monoclonal (clone GIH-3) anti-CDK9, 1:50 (datasheet M00794) |
| Primary incubation | Overnight at 4 °C (datasheet M00794) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M00794) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CDK9-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet M00794). Published alternatives use pH 9.0 or citrate pH 6.0 with other CDK9 antibodies (PMC8136118; PMC6865572).
Section 2
What Is the Expected CDK9 Staining Pattern?
CDK9 staining should be predominantly nuclear across many cell types: HPA describes ubiquitous nuclear expression and rates the tissue IHC pattern Supported, with high consistency between staining and RNA data (HPA: tissue IHC). Nuclear CDK9 fits its transcription role, although UniProt also places it in the cytoplasm and PML bodies (UniProt P50750: subcellular location). CDK9 has no transmembrane segment, so a membrane rim is not its expected pattern (UniProt P50750: topology).
| Many cells show clear nuclear chromogen, including glandular cells or bone marrow hematopoietic cells. | This fits the broad nuclear pattern (HPA: ubiquitous nuclear expression). HPA reports High staining in adrenal and breast glandular cells and bone marrow hematopoietic cells (HPA: tissue IHC). Compare nuclei with the counterstain before scoring; intensity alone does not establish specificity (standard IHC practice). |
| Signal is strongest at cell membranes or outside cells, with little nuclear staining. | Treat this as a suspect compartment pattern: CDK9 has no transmembrane segment, while HPA tissue IHC describes nuclear expression (UniProt P50750: topology; HPA: tissue IHC). Cytoplasmic CDK9 is possible, so cytoplasmic staining alone is less decisive; judge it against the nuclear signal and controls (UniProt P50750: subcellular location; standard IHC practice). |
| Only an unexpected cell population stains, while expected cells in the same section remain blank. | Check cell identity and the local HPA reference before calling cross-reactivity: CDK9 expression is broad, and the supplied HPA examples are not an exhaustive cell map (UniProt P50750: ubiquitous tissue specificity; HPA: tissue IHC). Discordant staining can reflect antibody cross-reactivity or endogenous detection activity; a reagent control helps distinguish them (standard IHC practice). |
| Chromogen appears as a diffuse haze over tissue or in reagent controls. | Haze that does not track nuclei is background, not a convincing CDK9 pattern (HPA: ubiquitous nuclear expression; standard IHC practice). Examine control sections for nonspecific antibody binding or endogenous detection activity before adjusting interpretation; the supplied sources do not identify a CDK9-specific cause (standard IHC practice). |
| A known-positive reference section has no convincing nuclear signal. | Do not score the run as a biological negative until the assay is checked (standard IHC practice). Adipocytes, bronchial respiratory epithelial cells and cerebellar granular-layer cells are among the supplied High HPA examples (HPA: tissue IHC). Failed detection, unsuitable dilution or retrieval conditions are general IHC possibilities, not demonstrated CDK9 fixation effects (standard IHC practice). |
💡Expected CDK9 appearanceCall a result positive when recognizable nuclei show clear staining across expected cell populations, with potentially strong signal in HPA High examples; diffuse tissue haze or a membrane rim is suspect (HPA: tissue IHC; UniProt P50750: topology; standard IHC practice).
| Tissue and cell context | HPA reports High staining in adipocytes, adrenal glandular cells, bronchial respiratory epithelial cells, caudate glial cells and cerebellar granular-layer cells (HPA: tissue IHC). These are useful reference populations; an unstated tissue is not an established negative (HPA: supplied tissue IHC examples). |
| Compartment | Expect predominantly nuclear tissue staining (HPA: ubiquitous nuclear expression). UniProt also records cytoplasm and PML bodies, including chromatin accumulation under replication stress; those annotations do not predict the frequency or intensity of such features in routine sections (UniProt P50750: subcellular location). |
| Antibody validation | The supplied HPA entries rate IHC for HPA006738 and CAB004216 Supported (HPA: antibody validation). That supports use as comparison evidence but does not, by itself, prove every stained structure is CDK9 or establish a particular retrieval condition (HPA: antibody validation; standard IHC practice). |
| Isoforms and epitope coverage | UniProt lists two CDK9 isoforms, but the supplied evidence gives no antibody epitope or isoform-specific staining comparison (UniProt P50750: isoforms; HPA: supplied antibody entries). Interpret a section as CDK9 staining without assigning signal to an isoform. |
| IF/ICC Q: What location should fluorescence show? | A: HPA calls the nucleoplasm the approved main location and cytoplasmic bodies an uncertain additional location (HPA: ICC-IF subcellular). UniProt also records nuclear and cytoplasmic CDK9 (UniProt P50750: subcellular location). This location check does not define an IF protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear staining in an HPA High reference population. | The detection workflow may have failed; the supplied evidence does not establish CDK9-specific fixation sensitivity (HPA: tissue IHC; standard IHC practice). | Verify section and reagent controls, then review the antibody's documented IHC-P dilution and retrieval procedure before changing conditions (standard IHC practice). |
| Diffuse brown signal obscures nuclear boundaries. | Nonspecific binding or endogenous detection activity can create background in chromogenic IHC (standard IHC practice). | Inspect reagent controls; review blocking, washes and detection chemistry, then rescore only nuclei that remain distinct from background (standard IHC practice; HPA: ubiquitous nuclear expression). |
| Signal follows membranes or extracellular material. | That distribution conflicts with HPA's nuclear tissue profile and CDK9's lack of a transmembrane segment (HPA: tissue IHC; UniProt P50750: topology). | Check the counterstain and reagent controls, and compare a known-positive section before accepting the pattern as CDK9 (standard IHC practice; HPA: tissue IHC). |
| Cytoplasmic staining is present alongside weak nuclear staining. | UniProt permits cytoplasmic CDK9, but HPA describes ubiquitous nuclear tissue expression (UniProt P50750: subcellular location; HPA: tissue IHC). | Record nuclear and cytoplasmic staining separately; compare the nuclear pattern with a reference section and avoid treating cytoplasm alone as definitive positivity (standard IHC practice; HPA: tissue IHC). |
| Only one cell group stains in an otherwise expected-positive field. | The supplied HPA examples may not cover every cell group; cross-reactivity or endogenous detection activity is also possible (HPA: tissue IHC; standard IHC practice). | Confirm cell identity, compare the matching HPA tissue example if available, and inspect reagent controls before assigning biological specificity (HPA: tissue IHC; standard IHC practice). |
| The section appears uniformly positive, making intensity scoring difficult. | Broad expression can yield many positive nuclei, while excess background can reduce contrast (HPA: ubiquitous nuclear expression; standard IHC practice). | Score recognizable nuclear signal against local background and the counterstain; use the same scoring rule across sections (standard IHC practice; HPA: ubiquitous nuclear expression). |
Experiment evidence
IHC & IF images showing CDK9 staining
M00794 · IHCIHC analysis of CDK9 using anti-CDK9 antibody (M00794). CDK9 was detected in a paraffin-embedded section of human breast cancer tissue. Heat
M00794 · IHCIHC analysis of CDK9 using anti-CDK9 antibody (M00794). CDK9 was detected in a paraffin-embedded section of human prostate cancer tissue. He
PB9537 · IHCIHC analysis of Cdk9 using anti-Cdk9 antibody (PB9537). Cdk9 was detected in a paraffin-embedded section of rat intestine tissue. Heat media
PB9537 · IHCIHC analysis of Cdk9 using anti-Cdk9 antibody (PB9537). Cdk9 was detected in a paraffin-embedded section of human intestinal cancer tissue.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/cerebral+cortex#imid_2106784
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/colon#imid_2106694
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/liver#imid_2106711
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000136807-CDK9/tissue/kidney#imid_2106704
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA006738; green = CDK9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA006738; green = CDK9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CDK9 IHC & IF
🧪Run breast tissue first; glandular cells should stain (HPA: High in breast glandular cells). HPA detects CDK9 in all 45 scored tissues, so there is no supported negative tissue or reliably negative cell type within the positive slide; use no-primary and isotype controls to judge background (HPA: no negative tissue rows; UniProt P50750: ubiquitous tissue specificity).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: CDK9 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CDK9 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include a secondary-only slide with no primary antibody, a species- and isotype-matched nonimmune rabbit IgG control, and a CDK9 knockout specimen as a biological negative (caption: rabbit anti-CDK9 antibody; standard IHC practice). Quench endogenous peroxidase and compare any DAB staining in blood-containing areas of the breast section with the no-primary slide (caption: HRP/DAB detection; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected M00794 tissue-IHC caption does not state the fixative (caption: fixative unreported). The paraffin-section example uses heat retrieval in EDTA at pH 8.0, but the evidence does not establish whether retrieval is required for every specimen (caption: EDTA retrieval, pH 8.0). HPA reports ICC-IF images but provides no basis to conclude that IF or frozen sections are easier; in breast tissue, check blood-containing areas for endogenous peroxidase background when interpreting DAB staining (HPA: ICC-IF images in A-431, U-251MG and U2OS; standard IHC practice).
HPA tissue IHC evidence for CDK9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: CDK9 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced CDK9 IHC Tips
Troubleshoot CDK9 staining in paraffin sections by checking retrieval, compartment, controls, and cell-level scoring before interpreting chromogenic signal.
What retrieval should I try first when CDK9 staining is weak in paraffin sections?
Use heat-mediated retrieval in EDTA buffer at pH 8.0 first (datasheet M00794). The selected paraffin-section example used that retrieval before overnight incubation at 4°C with antibody diluted 1:50, providing a starting workflow rather than a guaranteed setting for every specimen (datasheet M00794). If nuclear staining remains weak, compare retrieval duration on matched sections while holding antibody dilution and detection constant; monitor tissue damage and nonspecific staining as retrieval increases (standard IHC practice). Score nuclei separately from cytoplasm, because CDK9 is mainly nucleoplasmic and can also occur in the cytoplasm (HPA subcellular; UniProt P50750 localisation).
Could fixation explain weak or uneven CDK9 staining?
Target-specific CDK9 sensitivity to fixation is unknown from the supplied evidence; the selected paraffin-section caption does not state its fixative (datasheet M00794). Record the actual fixative, time in fixative, and processing history for each specimen, then compare sections processed together when investigating uneven staining (standard IHC practice). Keep retrieval at EDTA pH 8.0 and the initial antibody dilution at 1:50 during that comparison so fewer variables change (datasheet M00794). Examine staining alongside morphology and an independently validated control section; damaged areas cannot establish a fixation effect on CDK9 (standard IHC practice).
Should I count cytoplasmic CDK9 staining as a positive result?
Score nuclear and cytoplasmic staining separately: CDK9 is mainly nucleoplasmic, while UniProt also reports cytoplasmic CDK9 and context-dependent nuclear structures (HPA subcellular; UniProt P50750 localisation). Uncomplexed CDK9 can occur in the cytoplasm, whereas CDK9 complexed with CCNT1 occurs in nuclear speckles (UniProt P50750 localisation). Inspect intact cells at high magnification and compare each compartment with the tissue pattern and control section; diffuse chromogen over damaged tissue is difficult to assign to cells (standard IHC practice). Report the percentage of positive nuclei and cytoplasmic staining separately, using the same threshold across specimens (standard IHC practice).
Can this antibody distinguish CDK9 isoforms or modified CDK9 in tissue?
The supplied caption establishes staining of a paraffin section with M00794 but does not map its epitope or demonstrate isoform specificity (datasheet M00794). UniProt lists 2 CDK9 isoforms, a protein kinase domain at residues 19–315, and several modified residues, including phosphothreonine at 186 (UniProt P50750). Those annotations alone cannot show which molecular forms contribute to chromogenic staining (UniProt P50750; standard IHC interpretation). For an isoform or modification claim, obtain epitope documentation and validate specificity with appropriately matched controls; describe the current result as CDK9 immunoreactivity (standard IHC practice).
How should I adapt CDK9 localisation checks for a separate IF experiment?
Treat IF/ICC as a separate assay and validate its staining conditions independently; the M00794 caption documents chromogenic paraffin-section IHC (datasheet M00794). Multiplex CDK9 with a validated marker of the cell population being assessed, such as glandular cells in a breast specimen, and include a nuclear counterstain to assign signal to cells (HPA tissue IHC: High in breast glandular cells; standard IF practice). Choose a fluorophore channel with low tissue autofluorescence and check single-stain and no-primary controls for bleed-through or background (standard IF practice). Because CDK9 lacks a transmembrane segment and is mainly nucleoplasmic, optimise permeabilisation for an intracellular epitope while checking preservation of cell morphology (UniProt P50750 topology; HPA subcellular; standard IF practice).
How can I reduce diffuse or granular background in CDK9 DAB staining?
Start with matched no-primary and secondary-only controls to locate background from the detection system, then inspect whether signal follows intact nuclei (standard IHC practice; HPA subcellular). The selected example blocked with 10% goat serum, used M00794 at 1:50 overnight at 4°C, and developed signal with peroxidase and DAB (datasheet M00794). Include a peroxidase block and optimise washing and DAB development against a control section; these are general chromogenic workflow steps (standard IHC practice). If background persists, titrate primary antibody and assess tissue edges or damaged areas before changing the CDK9 scoring threshold (standard IHC practice).
What is a defensible way to quantify CDK9 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, since CDK9 is broadly expressed and predominantly nuclear (UniProt P50750 tissue specificity; HPA tissue IHC; HPA subcellular). For nuclear staining, record percent-positive nuclei and intensity grades, then calculate an H-score from 0–300 using the same thresholds for all specimens (standard IHC practice). Alternatively, report positive-cell density per mm² when cell abundance varies, with the counted tissue area and exclusion criteria stated (standard IHC practice). Normalise counts to eligible intact cells or analysed tissue area, and assess cytoplasmic staining separately to avoid conflating compartments (standard IHC practice; UniProt P50750 localisation).
How do I distinguish genuine CDK9 staining from a tissue artefact?
Expect staining in nuclei across many cell populations, with possible cytoplasmic signal, rather than treating every brown deposit as CDK9 (HPA tissue IHC: ubiquitous nuclear expression; UniProt P50750 localisation). Check whether positive cells are morphologically intact and whether the pattern repeats away from section edges and necrotic regions (standard IHC practice). Compare with a no-primary control and a peroxidase-blocked control to identify detection background or endogenous enzyme activity (standard IHC practice). A strong signal restricted to damaged areas, tissue edges, or a compartment inconsistent with the expected nuclear pattern warrants technical review before biological interpretation (HPA subcellular; standard IHC practice).
Boster reagents
Best CDK9 / Cyclin-dependent kinase 9 IHC Antibodies
Both antibodies have IHC images from paraffin sections (M00794/PB9537 image captions); M00794 also lists ICC/IF for human, mouse and rat, though no IF figure is supplied (M00794 catalog).
Real IHC data
Anti-CDK9 Rabbit Monoclonal Antibody
Cat # M00794
Real IHC data
Anti-Cdk9 Antibody ®
Cat # PB9537
M00794 has IHC images of human breast and prostate cancer, mouse brain and rat brain paraffin sections (M00794 image captions). PB9537 has IHC images of rat intestine and human intestinal cancer paraffin sections (PB9537 image captions).
Which to pick: For tissue IHC, choose M00794 for its rabbit monoclonal clone GIH-3 and human, mouse and rat reactivity, or PB9537 for human or rat samples (catalog applications/reactivity; M00794 clone; M00794/PB9537 image captions). For IF/ICC, choose M00794 because it lists both applications; PB9537 does not, and neither product supplies an IF figure (catalog applications/image records). Both IHC captions show paraffin sections with EDTA retrieval, but neither reports the fixative (M00794/PB9537 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P50750 (CDK9_HUMAN, Cyclin-dependent kinase 9).
- Human Protein Atlas. CDK9 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. CDK9 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytoplasmic bodies..
- Human Protein Atlas. CDK9 antibody validation summary (2 antibodies).
- Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer. Biomedicines 2023 — PMC10045754.
- Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer. Journal of ovarian research 2021 — PMC8136118.
- Targeting CDK9: A novel biomarker in the treatment of endometrial cancer. Oncology reports 2020 — PMC7551504.
- Cyclin-dependent kinase 9 expression and its association with CD8(+) T cell infiltration in microsatellite-stable colorectal cancer. Oncology letters 2019 — PMC6865572.
- PubMed PMID:8170997 — UniProt-cited evidence.
- PubMed PMID:7695608 — UniProt-cited evidence.
- PubMed PMID:10903437 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CDK9 (Cyclin-dependent kinase 9). Expected localisation Ubiquitous nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M00794). Validated IHC antibody: M00794 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M00794); 2. Fixation: Image fixative and duration unreported (datasheet M00794); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M00794); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M00794); 8. Primary antibody: Rabbit monoclonal (clone GIH-3) anti-CDK9, 1:50 (datasheet M00794); 9. Primary incubation: Overnight at 4 °C (datasheet M00794). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Cytoplasmic translocation may alter nuclear signal (UniProt); Isoform / epitope: 2 isoforms; check epitope coverage for each (UniProt); Regulation: Replication stress recruits CDK9 to chromatin (UniProt). Evidence: UniProt P50750, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M00794, PMC10045754, PMC8136118. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CDK9/immunohistochemistry-ihc-guide.